Enfamil Growth Paces Strong Nutritionals Performance For Bristol-Myers
This article was originally published in The Tan Sheet
Bristol-Myers Squibb's Enfamil infant formula brand posted sales growth of 24% to $175 mil. in the fourth quarter, contributing to a continued strong showing by the company's nutritional business. Quarterly sales in the U.S. increased 19% to $150 mil. For the year, Enfamil sales were up 13%, totaling $621 mil. worldwide, while U.S. sales rose 10% to $560 mil.
You may also be interested in...
Bristol-Myers Squibb's Excedrin Migraine indication for full migraine syndrome was approved by FDA Oct. 7. The new labeling simply bears the indication "Treats migraine."
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning